Skip to Main Content

Top executives for genome-editing companies on Monday pushed back against a new unpublished paper that raised concerns about preexisting immune responses to CRISPR-based therapies, insisting the issues outlined in the study were either already being addressed or were not relevant to the medicines being developed.

The paper, which was posted Friday on the preprint site bioRxiv, sent shares of Intellia Therapeutics and Editas Medicine down sharply Monday morning. Shares of CRISPR Therapeutics also declined.


The paper found that many people have preexisting antibodies and T cells geared to target certain proteins commonly used in CRISPR-Cas9 therapies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!